| [1] |
ESLAM M, SANYAL A J, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312 .
doi: 10.1053/j.gastro.2019.11.312
|
| [2] |
佘莎,戴锴. 《APASL临床实践指南:代谢相关脂肪性肝病的诊断和治疗(2025年版)》更新要点解读[J]. 中国临床医生杂志,2025,53(5): 51-54. doi: 10.3969/j.issn.2095-8552. 2025. 05.011 .
doi: 10.3969/j.issn.2095-8552. 2025. 05.011
|
| [3] |
ONISHI S, FUKUDA A, MATSUI M, et al. Body composition analysis in patients with metabolic dysfunction-associated fatty liver disease[J]. Nutrients, 2023, 15(18): 3878. doi: 10.3390/nu15183878 .
doi: 10.3390/nu15183878
|
| [4] |
ZHANG X, HE Z, SI Q, et al. The association of sarcopenia and visceral obesity with lean nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2022, 2022: 2229139. doi: 10.1155/2022/2229139 .
doi: 10.1155/2022/2229139
|
| [5] |
CHEN C, XIE L, ZHANG M, et al. The interplay between the muscle and liver in the regulation of glucolipid metabolism[J]. J Mol Cell Biol, 2024, 15(12): mjad073. doi: 10.1093/jmcb/mjad073 .
doi: 10.1093/jmcb/mjad073
|
| [6] |
JUNG C H, RHEE E J, KWON H, et al. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis[J]. Endocrinol Metab, 2020, 35(1): 165-176. doi:10.3803/EnM.2020.35.1.165 .
doi: 10.3803/EnM.2020.35.1.165
|
| [7] |
HAO X Y, ZHANG K, HUANG X Y, et al. Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease[J].World J Gastroenterol, 2024, 30(7): 636-643. doi: 10.3748/wjg.v30.i7.636 .
doi: 10.3748/wjg.v30.i7.636
|
| [8] |
TAO J, LI H, WANG H, et al. Metabolic dysfunction-associated fatty liver disease and osteoporosis: The mechanisms and roles of adiposity[J]. Osteoporos Int, 2024, 35(12): 2087-2098. doi: 10.1007/s00198-024-07217-y .
doi: 10.1007/s00198-024-07217-y
|
| [9] |
MOURTZAKIS M, PRADO C M M, LIEFFERS J R, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care[J]. Appl Physiol Nutr Metab, 2008, 33(5): 997-1006. doi: 10.1139/H08-075 .
doi: 10.1139/H08-075
|
| [10] |
CAREY E J, LAI J C, WANG C W, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl, 2017, 23(5): 625-633. doi: 10.1002/lt.24750 .
doi: 10.1002/lt.24750
|
| [11] |
HSIEH Y C, JOO S K, KOO B K, et al. Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease[J]. Liver Int, 2021, 41(3): 494-504. doi: 10.1111/liv.14719 .
doi: 10.1111/liv.14719
|
| [12] |
NACHIT M, HORSMANS Y, SUMMERS R M, et al. AI-based CT body composition identifies myosteatosis as key mortality predictor in asymptomatic adults[J]. Radiology, 2023, 307(5): e222008. doi: 10.1148/radiol.222008 .
doi: 10.1148/radiol.222008
|
| [13] |
KIM E H, KIM H K, LEE M J, et al. Sex differences of visceral fat area and visceral-to-subcutaneous fat ratio for the risk of incident type 2 diabetes mellitus[J]. Diabetes Metab J, 2022, 46(3): 486-498. doi: 10.4093/dmj.2021.0195 .
doi: 10.4093/dmj.2021.0195
|
| [14] |
中华医学会健康管理学分会, 国家骨科医学中心(首都医科大学附属北京积水潭医院), 国家级放射影像专业质控中心, 等. 定量 CT 在健康管理中的应用指南(2024)[J]. 中华健康管理学杂志, 2024,18(9): 645-654. doi:10.3760/cma.j.cn115624- 20240607-00474 .
doi: 10.3760/cma.j.cn115624- 20240607-00474
|
| [15] |
STERLING R K, LISSEN E, CLUMECK N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection[J]. Hepatology, 2006, 43(6): 1317-1325. doi: 10.1002/hep.21178 .
doi: 10.1002/hep.21178
|
| [16] |
MUSIO A, PERAZZA F, LEONI L, et al. Osteosarcopenia in NAFLD/MAFLD: An underappreciated clinical problem in chronic liver disease[J]. Int J Mol Sci, 2023, 24(8): 7517. doi: 10.3390/ijms24087517 .
doi: 10.3390/ijms24087517
|
| [17] |
ZHOU T, YE J, LUO L, et al. Restoring skeletal muscle mass as an independent determinant of liver fat deposition improvement in MAFLD[J]. Skeletal Muscle, 2023, 13(1): 23. doi: 10.1186/s13395-023-00333-z .
doi: 10.1186/s13395-023-00333-z
|
| [18] |
KIM G, LEE S, LEE Y, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A 7-year longitudinal study[J]. Hepatology, 2018, 68(5): 1755-1768. doi: 10.1002/hep.30049 .
doi: 10.1002/hep.30049
|
| [19] |
VISWANATH A, FOUDA S, FERNANDEZ C J, et al. Metabolic-associated fatty liver disease and sarcopenia: A double whammy[J]. World J Hepatol, 2024, 16(2): 152-163. doi: 10.4254/wjh.v16.i2.152 .
doi: 10.4254/wjh.v16.i2.152
|
| [20] |
FENG Z, ZHAO F, WANG Z, et al. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations[J]. BMC Gastroenterol, 2024, 24(1): 111. doi: 10.1186/s12876-024-03192-0 .
doi: 10.1186/s12876-024-03192-0
|
| [21] |
MALIK A, JAVAID S, MALIK M I, et al. Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis[J]. Ann Hepatol, 2024, 29: 101544. doi: 10.1016/j.aohep. 2024. 101544 .
doi: 10.1016/j.aohep. 2024. 101544
|
| [22] |
FERENC K, JARMKIEWICZ-CZAJA S, FILIP R. What does sarcopenia have to do with nonalcoholic fatty liver disease?[J]. Life, 2023, 14: 37. doi: 10.3390/life14010037 .
doi: 10.3390/life14010037
|
| [23] |
LOSASSO M R, PARUSSOLO M L C, SILVA A O, et al. Unraveling the metabolic pathways between metabolic-associated fatty liver disease (MAFLD) and sarcopenia[J].Int J Mol Sci, 2025, 26(10): 4673. doi: 10.3390/ijms26104673 .
doi: 10.3390/ijms26104673
|
| [24] |
KIM T H, JEONG C W, LEE C, et al. Association between body composition contents and hepatic fibrosis in sarcopenic obesity[J]. J Clin Med, 2023, 12(13): 4279. doi: 10.3390/jcm12134279 .
doi: 10.3390/jcm12134279
|
| [25] |
LEE S, KIM K W, LEE J, et al. Reduction of visceral adiposity as a predictor for resolution of nonalcoholic fatty liver in potential living liver donors[J]. Liver Transpl, 2021, 27(10): 1424-1431. doi: 10.1002/lt.26071 .
doi: 10.1002/lt.26071
|
| [26] |
KENĐEL JOVANOVIĆ G, MRAKOVCIC-SUTIC I, PAVIČIĆ ŽEŽELJ S, et al. Metabolic and hepatic effects of energy-reduced anti-inflammatory diet in younger adults with obesity[J]. Can J Gastroenterol Hepatol, 2021, 2021:6649142. doi: 10.1155/2021/6649142 .
doi: 10.1155/2021/6649142
|
| [27] |
HONG Y, CHEN X, WANG L, et al. Machine learning prediction of metabolic dysfunction-associated fatty liver disease risk in American adults using body composition: Explainable analysis based on SHapley Additive exPlanations[J]. Front Nutr, 2025, 12: 1616229. doi: 10.3389/fnut.2025.1616229 .
doi: 10.3389/fnut.2025.1616229
|
| [28] |
MÁTIS D, HEGYI P, TEUTSCH B, et al. Improved body composition decreases the fat content in non-alcoholic fatty liver disease, a meta-analysis and systematic review of longitudinal studies[J]. Front Med, 2023, 10: 1114836. doi: 10.3389/fmed. 2023.1114836 .
doi: 10.3389/fmed. 2023.1114836
|
| [29] |
YOKOKAWA H, FUKUDA H, SAITA M, et al. An association between visceral or subcutaneous fat accumulation and diabetes mellitus among Japanese subjects[J]. Diabetol Metab Syndr, 2021, 13(1): 44. doi: 10.1186/s13098-021-00646-3 .
doi: 10.1186/s13098-021-00646-3
|
| [30] |
ELGUEZABAL RODELO R G, PORCHIA L M, TORRAS-RASGADO E, et al. Visceral and subcutaneous abdominal fat is associated with non-alcoholic fatty liver disease while augmenting metabolic syndrome's effect on non-alcoholic fatty liver disease: A cross-sectional study of NHANES 2017–2018[J]. PLoS One, 2024, 19(2): e0298662. doi: 10.1371/journal.pone.0298662 .
doi: 10.1371/journal.pone.0298662
|
| [31] |
ZHANG W, LI Y, LI S, et al. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients[J]. Front Endocrinol, 2023, 14: 1278505. doi: 10.3389/fendo.2023.1278505 .
doi: 10.3389/fendo.2023.1278505
|